Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
1999-08-05
2004-03-02
Kemmerer, Elizabeth (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S085100, C514S002600, C536S023100, C536S023500, C530S300000
Reexamination Certificate
active
06699466
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to IL-16 antagonists and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases. In particular, the present invention relates to the discovery of IL-16 antagonist peptides whose sequences coincide with the C-terminal region of IL-16.
BACKGROUND OF THE INVENTION
Interleukin-16 (IL-16), previously named lymphocyte chemoattractant factor (or LCF), is a pro-inflammatory lymphokine with chemoattractant activity for resting CD4
+
T lymphocytes. Subsequent studies indicate that IL-16 activates signal transduction in CD4
+
target cells including monocytes, eosinophils and pro-B cells, and stimulates a variety of biological activities in addition to chemotaxis. Among these activities are inhibition of retroviral replication (Maciaszek, et al.,
J. Immunol
. 158:5, 1997; Zhou, et al.,
Nature Medicine
3:659, 1997 and Baier, et al.,
Nature
378:563, 1995), upregulation of IL-2R and synergy with IL-2 for CD4
+
T cell proliferation (Parada, et al.,
J. Immunol
. 160:2115, 1998), induction of RAG-1 and RAG-2 expression in CD4
+
pro-B cells (Szabo, et al.,
J. Immunol
., 161:2248, 1998), and transient inhibition of Mixed Lymphocyte Reaction (MLR)(Theodore, et al.,
J. Immunol
. 157:1958, 1996). Investigation of certain human diseases and experimental murine models indicates that IL-16 participates in inflammatory conditions characterized by tissue recruitment of CD4
+
T lymphocytes and other CD4
+
cell types. Conditions where IL-16 has been identified by ELISA and/or bioassay of body fluids, or by immunohistochemical and in situ hybridization techniques, include bronchial asthma (Laherge et al.,
Am. J. Respir. Cell. Mol. Biol
. 17: 193, 1997), inflammatory bowel disease (Keates et al.,
Gastroenterology
112, A110, 1997), Graves' disease (Cruikshank et al.,
J. Allergy Clin. Immunol
. 99: 554, 1997), multiple sclerosis (Biddison et al.,
J. Immunol
. 158: 3046, 1997) and bullous pemphigoid (Center et al.,
J. Invest. Dermatol.
81: 204, 1983). IL-16 is also implicated in the pathogenesis of rheumatoid arthritis (Klimiuk et al.,
J. Immunol
. 162: 4293-4299, 1999) and lupus (Lee et al.,
British J. Rheumatology
37: 1334-1337, 1998). Thus, it would be desirable to identify and/or generate reagents capable of interfering with the IL-16 activity for the purpose of treating inflammatory diseases.
The predicted amino acid sequence of IL-16 contains a central PDZ module, and structural studies confirm that IL-16 assumes a core PDZ-like conformation with flexible N-terminal and C-terminal tails of 17 and 14 residues, respectively (Muhlhahn et al.,
Nature Structural Biology
5:682, 1998)). A synthetic oligopeptide corresponding to the 16 C-terminal amino acids of human IL-16 (Arg106 to Ser121) has been reported to inhibit the chemoattractant activity of natural and recombinant human or murine IL-16 (Keane et al.,
J. Immunol
. 160:5945, 1998).
The present invention demonstrates that a series of peptides corresponding to native or substituted sequences of the C-terminus of IL-16 can inhibit IL-16 activity. Compositions and methods useful for treating IL-16 mediated disorders are exploited using these peptides.
SUMMARY OF THE INVENTION
One embodiment of the present invention is directed to IL-16 antagonists.
Another embodiment of the present invention is directed to IL-16 antagonist peptides.
The IL-16 antagonist peptides of the present invention are at least 4 amino acids in length and substantially correspond to the C-terminal sequence of human or murine IL-16 surrounding the Arg/Lys-Arg motif, i.e., R
106
-R
107
of human IL-16, R
103
-R
104
of murine IL-16 or K
106
-R
107
of IL-16 from squirrel monkey, for example.
A preferred IL-16 antagonist peptide of the present invention is the tetrameric peptide X
aa0
RX
aa1
X
aa2
(SEQ ID NO:1), wherein X
aa0
is Arg or Lys, and X
aa1
and X
aa2
can be any amino acid. Preferably, X
aa1
and X
aa2
are those amino acids found in the native sequence of a mammalian IL-16, such as Lys or Thr for X
aa1
, and Ser for X
aa2
.
More preferably, X
aa0
RX
aa1
X
aa2
is a tetramer having a sequence which coincides with the native sequence of a mammalian IL-16, e.g., RRKS (SEQ ID NO:2), RRTS (SEQ ID NO:3), or KRKS (SEQ ID NO:4). Even more preferably, such tetramer has Arg as the first amino acid. Homologs and analogs of the tetramers of SEQ ID NO:2-4 are also contemplated by the present invention. For example, analogs of RRKS (SEQ ID NO:2) include RRAS (SEQ ID NO:5) and RRKA (SEQ ID NO:6).
Another preferred IL-16 antagonist peptide of the present invention is a tetrameric peptide having the sequence of X
aa1
X
aa2
X
aa0
R (SEQ ID NO:8), wherein X
aa0
is Arg or Lys, and X
aa1
and X
aa2
can be any amino acid.
Preferably, X
aa1
and X
aa2
are those amino acids found in the native sequence of a mammalian IL-16, e.g., Val for X
aa1
, and Ile or Leu for X
aa2
.
More preferably, X
aa1
X
aa2
X
aa0
R is a tetramer having a sequence which coincides with the native sequence of a mammalian IL-16, such as VIRR (SEQ ID NO:9), VLRR (SEQ ID NO:10) and VIKR (SEQ ID NO:11). Even more preferably, such tetramer has Arg as the first amino acid. Homologs and analogs of these tetramers (SEQ ID NOS:9-11) are also contemplated by the present invention.
Still another preferred IL-16 antagonist peptide of the present invention is a tetrameric peptide having the sequence of X
aa1
X
aa0
RX
aa2
(SEQ ID NO:12), wherein X
aa0
is Arg or Lys, and X
aa1
and X
aa2
can be any one amino acid. Preferably, X
aa1
and X
aa2
are those amino acids found in the native sequence of a mammalian IL-16. For example, X
aa1
can be Ile or Leu, and X
aa2
can be Lys or Thr.
More preferably, X
aa1
X
aa2
X
aa0
R is a tetramer having a sequence which coincides with the native sequence of an IL-16, such as IRRK (SEQ ID NO:13), IRRT (SEQ ID NO:14), LRRK (SEQ ID NO:15), and IKRK (SEQ ID NO:16). Even more preferably, such tetramer has Arg as the first amino acid. Homologs and analogs of such tetramers are also contemplated by the present invention.
Further according to the present invention, an IL-16 antagonist peptide can be longer than a tetramer, as long as the such antagonist peptide contains one of the tetrameric sequences described hereinabove, i.e., X
aa0
RX
aa1
X
aa2
(SEQ ID NO:1), X
aa1
X
aa0
RX
aa2
(SEQ ID NO:8) or X
aa1
X
aa2
X
aa0
R (SEQ ID NO:12), and as long as such peptide antagonizes at least one IL-16 biological activity.
Nucleic acid molecules coding for any of the above IL-16 antagonist peptide of the present invention, expression vectors which include any of such nucleic acid molecules, as well as related host cells containing such nucleotide sequences or vectors, are also contemplated by the present invention.
In a further aspect, the present invention provides antibodies directed against the IL-16 antagonist peptides of the present invention.
Preferably, the antibodies of the present invention are raised against those IL-16 antagonist peptides whose sequences coincide with the corresponding sequences of a mammalian IL-16 protein, which antibodies can antagonize or neutralize the activity of IL-16. Both polyclonal antibodies and monoclonal antibodies are contemplated by the present invention.
Functional derivatives of the monoclonal antibodies of the present invention are also contemplated, including Fab, Fab′, F(ab′)
2
of the present mAbs, single chain antibodies, humanized antibodies and the like.
A related aspect of the present invention is directed to methods of raising antibodies specific for the IL-16 antagonist peptides of the present invention by using such peptides as immunogens.
In another embodiment, the present invention provides pharmaceutical compositions which include one or more of the IL-16 antagonist peptides or antibodies, and a pharmaceutically acceptable carrier. The pharmaceutical compositions of the present invention can also include other appropriate active ingredients, such as known anti-inflammatory agents, e.g., a
Center David M.
Cruikshank William W.
Kornfeld Hardy
Bunner Bridget E.
Kemmerer Elizabeth
Research Corporation Technologies Inc.
Scully Scott Murphy & Presser
LandOfFree
IL-16 antagonist peptides and DNA encoding the peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IL-16 antagonist peptides and DNA encoding the peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-16 antagonist peptides and DNA encoding the peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3249789